| Ytd | 82.86% | |
| 1y | -34.98% |
| Open | 4.54 | Prev Close | 4.49 | Low | 4.40 | High | 4.54 | Mkt Cap | 291.35M |
| Vol | 14.69K | Avg Vol | 548.39K | EPS | -0.92 | P/E | N/A | Forward P/E | -9.28 |
| Beta | 1.40 | Short Ratio | 3.26 | Inst. Own | 64.11% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 11-05 | 50-d Avg | 4.49 | 200-d Avg | 2.99 | 1yr Est | 7.96 |
TMCI News
Treace Medical Concepts, Inc. ("Treace" or the "Company") (NASDAQ:TMCI), a medical t
PONTE VEDRA, Fla., Sept. 17, 2026 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace” or the
New product offerings extend bunion market leadership and accelerate penetration into new foot & ank
Truist Securities analyst Richard Newitter maintains Treace Medical Concepts (NASDAQ:TMCI) with a
Treace Medical Concepts (NASDAQ:TMCI) reported quarterly losses of $(0.24) per share which beat the
Treace Medical Concepts (NASDAQ:TMCI) raises FY2026 sales outlook from $202.000 million-$212.000 mil
Truist Securities analyst Richard Newitter maintains Treace Medical Concepts (NASDAQ:TMCI) with a
HyperPlate™ fixation technology further advances the SpeedPlate® implant platform by incorporating F
Treace Medical Concepts (NASDAQ:TMCI) raises FY2026 sales outlook from $200.000 million-$212.000 mil
Treace Medical Concepts (NASDAQ:TMCI) reported quarterly losses of $(0.28) per share which beat the
US stocks mixed; Dow falls 0.29% as inflation rate surges to 3.3%. Materials up 0.8%, financials dow
Lake Street analyst Ben Haynor maintains Treace Medical Concepts (NASDAQ:TMCI) with a Buy and low
2026 Financial OutlookThe Company is initiating full-year 2026 revenue guidance of $200 million to $
Treace Medical Concepts (NASDAQ:TMCI) reported quarterly losses of $(0.15) per share which met the a
Treace Medical Concepts, Inc. ("Treace" or the "Company") (NasdaqGS: TMCI), a medica
Stifel analyst Rick Wise maintains Treace Medical Concepts (NASDAQ:TMCI) with a Hold and lowers t
Truist Securities analyst Richard Newitter maintains Treace Medical Concepts (NASDAQ:TMCI) with a
Treace Medical Concepts, Inc. ("Treace" or the "Company") (NASDAQ:TMCI), a medical t
Truist Securities analyst Richard Newitter reiterates Treace Medical Concepts (NASDAQ:TMCI) with
UBS analyst Danielle Antalffy maintains Treace Medical Concepts (NASDAQ:TMCI) with a Neutral and
JP Morgan analyst Lilia-Celine Lozada downgrades Treace Medical Concepts (NASDAQ:TMCI) from Neutr
Treace Medical Concepts (NASDAQ:TMCI) lowers FY2025 sales outlook from $224.000 million-$230.000 mil
Treace Medical Concepts (NASDAQ:TMCI) reported quarterly losses of $(0.26) per share which beat the
Truist Securities analyst Richard Newitter maintains Treace Medical Concepts (NASDAQ:TMCI) with a
Truist Securities analyst Richard Newitter maintains Treace Medical Concepts (NASDAQ:TMCI) with a
UBS analyst Danielle Antalffy maintains Treace Medical Concepts (NASDAQ:TMCI) with a Neutral and
Stifel analyst Rick Wise maintains Treace Medical Concepts (NASDAQ:TMCI) with a Hold and lowers t
Treace Medical Concepts (NASDAQ:TMCI) affirms FY2025 sales outlook from $224.000 million-$230.000 mi
Treace Medical Concepts (NASDAQ:TMCI) reported quarterly losses of $(0.28) per share which beat the
Treace Medical Concepts, Inc. ("Treace" or the "Company") (NASDAQ:TMCI), a medical t
Treace Medical Concepts, Inc. ("Treace" or the "Company") (NASDAQ:TMCI), a medical t
